BACKGROUND: The protein C pathway down-regulates thrombin generation and promotes cytoprotection during inflammation and stress. In preclinical studies using models of murine injury (e.g., sepsis and ischemic stroke), murine protein S may be required because of restrictive species specificity. DESIGN AND METHODS: We prepared and characterized recombinant murine protein S using novel coagulation assays, immunoassays, and cell proliferation assays. RESULTS: Purified murine protein S had good anticoagulant co-factor activity for murine activated protein C, but not for human activated protein C, in mouse or rat plasma. In human plasma, murine protein S was a poor co-factor for murine activated protein C and had no anticoagulant effect with human activated protein C, suggesting protein S species specificity for factor V in addition to activated protein C. We estimated that mouse plasma contains 22+/-1 microg/mL protein S and developed assays to measure activated protein C co-factor activity of the protein S in murine plasma. Activated protein C-independent anticoagulant activity of murine protein S was demonstrable and quantifiable in mouse plasma, and this activity was enhanced by exogenous murine protein S. Murine protein S promoted the proliferation of mouse and human smooth muscle cells. The potency of murine protein S was higher for mouse cells than for human cells and similarly, human protein S was more potent for human cells than for mouse cells. CONCLUSIONS: The spectrum of bioactivities of recombinant murine protein S with mouse plasma and smooth muscle cells is similar to that of human protein S. However, in vitro and in vivo studies of the protein C pathway in murine disease models are more appropriately performed using murine protein S. This study extends previous observations regarding the remarkable species specificity of protein S to the mouse.
BACKGROUND: The protein C pathway down-regulates thrombin generation and promotes cytoprotection during inflammation and stress. In preclinical studies using models of murine injury (e.g., sepsis and ischemic stroke), murine protein S may be required because of restrictive species specificity. DESIGN AND METHODS: We prepared and characterized recombinant murine protein S using novel coagulation assays, immunoassays, and cell proliferation assays. RESULTS: Purified murine protein S had good anticoagulant co-factor activity for murine activated protein C, but not for human activated protein C, in mouse or rat plasma. In human plasma, murine protein S was a poor co-factor for murine activated protein C and had no anticoagulant effect with human activated protein C, suggesting protein S species specificity for factor V in addition to activated protein C. We estimated that mouse plasma contains 22+/-1 microg/mL protein S and developed assays to measure activated protein C co-factor activity of the protein S in murine plasma. Activated protein C-independent anticoagulant activity of murine protein S was demonstrable and quantifiable in mouse plasma, and this activity was enhanced by exogenous murine protein S. Murine protein S promoted the proliferation of mouse and human smooth muscle cells. The potency of murine protein S was higher for mouse cells than for human cells and similarly, human protein S was more potent for human cells than for mouse cells. CONCLUSIONS: The spectrum of bioactivities of recombinant murine protein S with mouse plasma and smooth muscle cells is similar to that of human protein S. However, in vitro and in vivo studies of the protein C pathway in murine disease models are more appropriately performed using murine protein S. This study extends previous observations regarding the remarkable species specificity of protein S to the mouse.
Authors: Howard A Anderson; Caroline A Maylock; Joy A Williams; Cloud P Paweletz; Hongjun Shu; Emily Shacter Journal: Nat Immunol Date: 2002-11-25 Impact factor: 25.606
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: Christopher Doering; Ernest T Parker; John F Healey; Heather N Craddock; Rachel T Barrow; Pete Lollar Journal: Thromb Haemost Date: 2002-09 Impact factor: 5.249
Authors: Laurent O Mosnier; Antonella Zampolli; Edward J Kerschen; Reto A Schuepbach; Yajnavalka Banerjee; José A Fernández; Xia V Yang; Matthias Riewald; Hartmut Weiler; Zaverio M Ruggeri; John H Griffin Journal: Blood Date: 2009-02-24 Impact factor: 22.113
Authors: O Benzakour; C Formstone; S Rahman; C Kanthou; U Dennehy; M F Scully; V V Kakkar; D N Cooper Journal: Biochem J Date: 1995-06-01 Impact factor: 3.857
Authors: Sara Calzavarini; Raja Prince-Eladnani; François Saller; Luca Bologna; Laurent Burnier; Anne C Brisset; Claudia Quarroz; Maria Desiré Reina Caro; Vladimir Ermolayev; Yasuhiro Matsumura; José A Fernández; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer Journal: Blood Date: 2020-05-28 Impact factor: 22.113
Authors: Zhihui Zhong; Yaoming Wang; Huang Guo; Abhay Sagare; José A Fernández; Robert D Bell; Theresa M Barrett; John H Griffin; Robert S Freeman; Berislav V Zlokovic Journal: J Neurosci Date: 2010-11-17 Impact factor: 6.167
Authors: Mary J Heeb; Rolf M Mesters; José A Fernández; Tilman M Hackeng; Ryon K Nakasone; John H Griffin Journal: Thromb Haemost Date: 2013-05-23 Impact factor: 5.249
Authors: Huang Guo; Theresa M Barrett; Zhihui Zhong; José A Fernández; John H Griffin; Robert S Freeman; Berislav V Zlokovic Journal: Mol Neurodegener Date: 2011-02-03 Impact factor: 14.195
Authors: Annette von Drygalski; Vikas Bhat; Andrew J Gale; Laurent Burnier; Thomas J Cramer; John H Griffin; Laurent O Mosnier Journal: PLoS One Date: 2014-08-15 Impact factor: 3.240